Buy Sanofi India; target of Rs 8965: ICICI Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

ICICI Direct's research report on Sanofi India

Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, thrombosis, anti-infective, CNS, allergy, vitamins, minerals & supplements. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India • Sanofi is one of the fastest growing companies in India in anti-diabetic therapy.

Outlook

Retain BUY rating on the stock due to strong chronic (anti-diabetic in particular) franchise and downsized portfolio to focus on margins Valued at Rs 8965 i.e. 30x P/E on FY24E EPS on Rs 298.9.

More Info

At 12:18 hrs Sanofi India was quoting at Rs 7,192.90, up Rs 9.05, or 0.13 percent.

It has touched an intraday high of Rs 7,348.40 and an intraday low of Rs 7,192.90.

It was trading with volumes of 873 shares, compared to its thirty day average of 916 shares, a decrease of -4.67 percent.

In the previous trading session, the share closed down 1.29 percent or Rs 93.60 at Rs 7,183.85.

The share touched its 52-week high Rs 9,300.00 and 52-week low Rs 6,949.35 on 10 August, 2021 and 27 January, 2022, respectively.

Currently, it is trading 22.66 percent below its 52-week high and 3.5 percent above its 52-week low.

Market capitalisation stands at Rs 16,565.70 crore.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

Read More